Ilsung IS Co Ltd

Ilsung IS Co Ltd has a strong liquidity position, with a current ratio of 6.69, indicating that the company holds significantly more current assets than current liabilities. The company also maintains a substantial cash and equivalents balance of 131,000,565,450 KRW, which supports its short-term financial flexibility.

Despite its strong liquidity, the company reported a net loss of 666,647,820 KRW and an operating loss of 3,355,486,830 KRW in the latest period, indicating a decline in profitability. The return on equity (ROE) was -0.0018, and the return on assets (ROA) was -0.0016, both of which are below typical industry benchmarks for pharmaceutical companies.

The company's revenue for the period was 15,986,116,370 KRW, but there is no detailed breakdown of revenue by geographic region or business segment in the available data. This lack of segmentation makes it difficult to assess the geographic or product concentration of the company's revenue.

Looking ahead, the company's growth trajectory is uncertain due to its current financial performance. The operating cash flow was positive at 2,093,401,090 KRW, but the free cash flow was negative at -2,131,070,570 KRW, suggesting that the company is investing heavily in capital expenditures, which totaled -2,262,633,750 KRW.

The risk assessment indicates that the company has low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the negative net income and operating income suggest that the company may face challenges in maintaining profitability in the near term.

There are no recent events or filings mentioned in the available data that would provide additional insight into the company's operations or strategic direction. The absence of recent transcripts or filings limits the ability to assess any material changes in the company's business or financial condition.

Ilsung IS Co Ltd (003120.KS) has been formally classified within the Healthcare economic sector, specifically under the Pharmaceuticals & Medical Research activity. This medium-severity update establishes the company’s operational identity, providing a clearer framework for understanding its business focus and market positioning. Concurrently, the firm’s risk profile has been updated with new assessments indicating low dilution risk and low liquidity risk. These classifications, derived from standard thresholds, suggest a stable capital structure and adequate market depth, which are foundational elements for investor confidence in the stock’s stability. The combination of a defined sector classification and favorable risk metrics offers a more complete picture of the company’s fundamentals. By anchoring Ilsung IS in the healthcare sector while confirming low immediate financial risks, the data supports a view of the company as a specialized entity with manageable exposure to capital erosion or trading illiquidity. These updates serve as a baseline for further analysis, particularly given the absence of current analyst coverage or index membership data in the available records. The established sector and risk parameters provide essential context for evaluating future financial performance and strategic developments within the pharmaceutical and medical research landscape.

The company maintains a zero debt-to-equity ratio, ranking in the top quartile of the pharmaceutical cohort.

Free cash flow improved by 28.3% year-over-year, indicating better cash generation despite operating losses.

Revenue demonstrated a 11.2% compound annual growth rate over the four-year period ending in FY0.

The firm faces low dilution and liquidity risks, suggesting stable capital structure and market access.

Gross profit remained robust at 27.9 billion KRW in FY0, supporting potential margin recovery efforts.

The company carries a high credit risk flag, indicating potential difficulties in meeting financial obligations.

Cash conversion ratio of -3.14 ranks in the bottom quartile, highlighting poor cash generation efficiency.